Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jason Clark

Showing results (71-80 of 80) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 80 results.
Haematologica|October 30, 2016
Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosisJohn O Mascarenhas, Moshe Talpaz, Vikas Gupta, et al.
JCI Insight|February 15, 2017
Real-time genomic profiling of histiocytoses identifies early-kinase domain BRAF alterations while improving treatment outcomesLynn H Lee, Anjelika Gasilina, Jayeeta Roychoudhury, et al.
Vital and Health Statistics. Series 2, Data Evaluation and Methods Research|February 5, 2021
An Investigation of Nonresponse Bias and Survey Location Variability in the 2017-2018 National Health and Nutrition Examination SurveyTala H I Fakhouri, Crescent B Martin, Te-Ching Chen, et al.
BMC Cancer|July 25, 2024
Pembrolizumab plus either epacadostat or placebo for cisplatin-ineligible urothelial carcinoma: results from the ECHO-307/KEYNOTE-672 studyAndrea Necchi, Michiel S Van der Heijden, Dmytro Trukhin, et al.
Journal for Immunotherapy of Cancer|October 31, 2022
First-in-human phase I/II, open-label study of the anti-OX40 agonist INCAGN01949 in patients with advanced solid tumorsElizabeth J Davis, Juan Martin-Liberal, Rebecca Kristeleit, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 10, 2015
Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has FailedHerbert I Hurwitz, Nikhil Uppal, Stephanie A Wagner, et al.
Physical Review Letters|November 30, 2025
Fingerprints of Triaxiality in the Charge Radii of Neutron-Rich RutheniumBernhard Maass, Wouter Ryssens, Kristian König, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 4, 2011
A phase I pharmacokinetic and pharmacodynamic study of dalotuzumab (MK-0646), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in patients with advanced solid tumorsFrancesco Atzori, Josep Tabernero, Andrés Cervantes, et al.
Arthritis and Rheumatism|September 1, 2007
A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritisNicolino Ruperto, Daniel J Lovell, Ruben Cuttica, et al.
Cell Stem Cell|June 18, 2013
Molecular profiling of human mammary gland links breast cancer risk to a p27(+) cell population with progenitor characteristicsSibgat Choudhury, Vanessa Almendro, Vanessa F Merino, et al.
Pageof 8

Showing results (71-80 of 80) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 80 results.
Haematologica|October 30, 2016
Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosisJohn O Mascarenhas, Moshe Talpaz, Vikas Gupta, et al.
JCI Insight|February 15, 2017
Real-time genomic profiling of histiocytoses identifies early-kinase domain BRAF alterations while improving treatment outcomesLynn H Lee, Anjelika Gasilina, Jayeeta Roychoudhury, et al.
Vital and Health Statistics. Series 2, Data Evaluation and Methods Research|February 5, 2021
An Investigation of Nonresponse Bias and Survey Location Variability in the 2017-2018 National Health and Nutrition Examination SurveyTala H I Fakhouri, Crescent B Martin, Te-Ching Chen, et al.
BMC Cancer|July 25, 2024
Pembrolizumab plus either epacadostat or placebo for cisplatin-ineligible urothelial carcinoma: results from the ECHO-307/KEYNOTE-672 studyAndrea Necchi, Michiel S Van der Heijden, Dmytro Trukhin, et al.
Journal for Immunotherapy of Cancer|October 31, 2022
First-in-human phase I/II, open-label study of the anti-OX40 agonist INCAGN01949 in patients with advanced solid tumorsElizabeth J Davis, Juan Martin-Liberal, Rebecca Kristeleit, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 10, 2015
Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has FailedHerbert I Hurwitz, Nikhil Uppal, Stephanie A Wagner, et al.
Physical Review Letters|November 30, 2025
Fingerprints of Triaxiality in the Charge Radii of Neutron-Rich RutheniumBernhard Maass, Wouter Ryssens, Kristian König, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 4, 2011
A phase I pharmacokinetic and pharmacodynamic study of dalotuzumab (MK-0646), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in patients with advanced solid tumorsFrancesco Atzori, Josep Tabernero, Andrés Cervantes, et al.
Arthritis and Rheumatism|September 1, 2007
A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritisNicolino Ruperto, Daniel J Lovell, Ruben Cuttica, et al.
Cell Stem Cell|June 18, 2013
Molecular profiling of human mammary gland links breast cancer risk to a p27(+) cell population with progenitor characteristicsSibgat Choudhury, Vanessa Almendro, Vanessa F Merino, et al.
Pageof 8